Histone deacetylases (HDACs) are a class of enzymes that remove acetyl from the ε-N-
acetyl lysine of histones, allowing histones to wrap DNA more tightly. HDACs play an …

A significant advancement in the field of epigenetic drug discovery has been evidenced in
recent years. Epigenetic alterations are hereditary, nevertheless reversible variations to …

Histone methyltransferases (HMTs) play a critical role in gene post-translational regulation
and diverse physiological processes, and are implicated in a plethora of human diseases …

Epigenetic enzymes histone deacetylases (HDACs) are clinically validated anticancer drug
targets which have been studied intensively in the past few decades. Although several drugs …

Recently, despite the great success achieved by the so‐called “magic bullets” in the
treatment of different diseases through a marked and specific interaction with the target of …

Despite some advances in targeted therapeutics of human cancers, curative cancer
treatment still remains a tremendous challenge due to the occurrence of drug resistance. A …

Glioma is characterized by a high recurrence rate, short survival times, high rates of mortality
and treatment difficulties. Surgery, chemotherapy and radiation (RT) are the standard …

A plethora of preclinical evidences suggests that pharmacological targeting of epigenetic
dysregulation is a potent strategy to combat human diseases. Nevertheless, the …

Multitargeting involves the application of molecules that are deliberately intended to bind to
two or more unrelated cellular targets with high affinity. In epigenetic chemical biology and …

Abnormal epigenetics is a critical hallmark of human cancers. Anticancer drug discovery
directed at histone epigenetic modulators has gained impressive advances with six drugs …